nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

01.11.2014 | Review

Prediction and prevention of psychosis: current progress and future tasks

verfasst von: Stephan Ruhrmann, Frauke Schultze-Lutter, Stefanie J. Schmidt, Nathalie Kaiser, Joachim Klosterkötter

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Sonderheft 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Prevention of psychoses has been intensively investigated within the past two decades, and particularly, prediction has been much advanced. Depending on the applied risk indicators, current criteria are associated with average, yet significantly heterogeneous transition rates of ≥30 % within 3 years, further increasing with longer follow-up periods. Risk stratification offers a promising approach to advance current prediction as it can help to reduce heterogeneity of transition rates and to identify subgroups with specific needs and response patterns, enabling a targeted intervention. It may also be suitable to improve risk enrichment. Current results suggest the future implementation of multi-step risk algorithms combining sensitive risk detection by cognitive basic symptoms (COGDIS) and ultra-high-risk (UHR) criteria with additional individual risk estimation by a prognostic index that relies on further predictors such as additional clinical indicators, functional impairment, neurocognitive deficits, and EEG and structural MRI abnormalities, but also considers resilience factors. Simply combining COGDIS and UHR criteria in a second step of risk stratification produced already a 4-year hazard rate of 0.66. With regard to prevention, two recent meta-analyses demonstrated that preventive measures enable a reduction in 12-month transition rates by 54–56 % with most favorable numbers needed to treat of 9–10. Unfortunately, psychosocial functioning, another important target of preventive efforts, did not improve. However, these results are based on a relatively small number of trials; and more methodologically sound studies and a stronger consideration of individual profiles of clinical needs by modular intervention programs are required.

Addington J, Cornblatt BA, Cadenhead KS et al (2011) At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 168:800–805PubMedCrossRefPubMedCentral

Addington J, Epstein I, Liu L et al (2011) A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 125:54–61PubMedCrossRef

Amminger GP, Schafer MR, Papageorgiou K et al (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67:146–154PubMedCrossRef

Antonini L, Mollica C, Auriti A et al (2014) A prognostic index for risk stratification for acute heart failure and death in subjects with ischemic cardiomyopathy and cardiac defibrillator. Heart Vessels. doi:10.1007/s00380-014-0494-7 PubMed

Barch DM, Bustillo J, Gaebel W et al (2013) Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5. Schizophr Res 150:15–20PubMedCrossRef

Bechdolf A, Muller H, Stutzer H et al (2011) Rationale and baseline characteristics of prevent: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. Schizophr Bull 37(Suppl 2):S111–S121PubMedCrossRefPubMedCentral

Bechdolf A, Wagner M, Ruhrmann S et al (2012) Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry 200:22–29PubMedCrossRef

Bell RQ (1992) Multiple-risk cohorts and segmenting risk as solutions to the problem of false positives in risk for the major psychoses. Psychiatry 55:370–381PubMed

Bodatsch M, Ruhrmann S, Müller R, Klosterkötter J, Brockhaus-Dumke A (2010) Mismatch negativity is reduced in schizophrenia patients with deficit syndrome. Schizophr Res 117:360–361CrossRef

10.

Bodatsch M, Ruhrmann S, Wagner M et al (2011) Prediction of psychosis by mismatch negativity. Biol Psychiatry 69:959–966PubMedCrossRef

11.

Bourque F, van der Ven E, Fusar-Poli P, Malla A (2012) Immigration, social environment and onset of psychotic disorders. Curr Pharm Des 18:518–526PubMedCrossRef

12.

Brown AS (2011) The environment and susceptibility to schizophrenia. Prog Neurobiol 93:23–58PubMedCrossRefPubMedCentral

13.

Cannon TD, Cadenhead K, Cornblatt B et al (2008) Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in north America. Arch Gen Psychiatry 65:28–37PubMedCrossRefPubMedCentral

14.

Carrion RE, McLaughlin D, Goldberg TE et al (2013) Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry 70:1133–1142PubMedCrossRef

15.

Clouth J (2004) Kosten der frühverrentung am beispiel der schizophrenie [costs of early retirement: the case of schizophrenia]. Psychiatry Prax 31(Suppl 2):S238–S245CrossRef

16.

Cornblatt BA, Carrion RE, Addington J et al (2012) Risk factors for psychosis: impaired social and role functioning. Schizophr Bull 38:1247–1257PubMedCrossRefPubMedCentral

17.

Cornblatt BA, Lencz T, Smith CW et al (2003) The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull 29:633–651PubMedCrossRef

18.

Forhan M, Zagorski BM, Marzonlini S, Oh P, Alter DA (2013) Predicting exercise adherence for patients with obesity and diabetes referred to a cardiac rehabilitation and secondary prevention program. Can J Diabetes 37:189–194PubMedCrossRef

19.

Fusar-Poli P, Bechdolf A, Taylor MJ et al (2013) At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull 39:923–932PubMedCrossRefPubMedCentral

20.

Fusar-Poli P, Bonoldi I, Yung AR et al (2012) Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69:220–229PubMedCrossRef

21.

Fusar-Poli P, Borgwardt S, Bechdolf A et al (2013) The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 70:107–120PubMedCrossRef

22.

Fusar-Poli P, Deste G, Smieskova R et al (2012) Cognitive functioning in prodromal psychosis: a meta-analysis of cognitive functioning in prodromal psychosis. Arch Gen Psychiatry 69:562–571PubMed

23.

Gordon RS Jr (1983) An operational classification of disease prevention. Public Health Rep 98:107–109PubMedPubMedCentral

24.

Gustavsson A, Svensson M, Jacobi F et al (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:718–779PubMedCrossRef

25.

Häfner H, Maurer K, Löffler W et al (1998) The abc schizophrenia study: a preliminary overview of the results. Soc Psychiatry Psychiatry Epidemiol 33:380–386CrossRef

26.

Häfner H, Nowotny B, Loffler W, an der Heiden W, Maurer K (1995) When and how does schizophrenia produce social deficits? Eur Arch Psychiatry Clin Neurosci 246:17–28PubMedCrossRef

27.

Haro JM, Ayuso-Mateos JL, Bitter I et al (2014) Roamer: roadmap for mental health research in Europe. Int J method psychiatric res 23(Suppl 1):1–14CrossRef

28.

Howes OD, Fusar-Poli P, Bloomfield M, Selvaraj S, McGuire P (2012) From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments. Curr Pharm Des 18:459–465PubMedCrossRefPubMedCentral

29.

Hutton P, Taylor PJ (2014) Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. Psychol Med 44:449–468PubMedCrossRef

30.

Ising HK, Veling W, Loewy RL et al (2012) The validity of the 16-item version of the prodromal questionnaire (pq-16) to screen for ultra high risk of developing psychosis in the general help-seeking population. Schizophr Bull 38:1288–1296PubMedCrossRefPubMedCentral

31.

Jääskeläinen E, Juola P, Hirvonen N et al (2013) A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 39:1296–1306PubMedCrossRef

32.

Kidd SA (2013) From social experience to illness experience: reviewing the psychological mechanisms linking psychosis with social context. Can J psychiatry Revue canadienne de psychiatrie 58:52–58

33.

Kim KR, Song YY, Park JY et al (2013) The relationship between psychosocial functioning and resilience and negative symptoms in individuals at ultra-high risk for psychosis. Aust NZ J Psychiatry 47:762–771CrossRef

34.

Kirkbride JB, Fearon P, Morgan C et al (2006) Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch Gen Psychiatry 63:250–258PubMedCrossRef

35.

Klosterkötter J (2008) Indicated prevention of schizophrenia. Dtsch Arztebl Int 105:532–539PubMedPubMedCentral

36.

Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F (2001) Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 58:158–164PubMedCrossRef

37.

Klosterkötter J, Schultze-Lutter F (2010) Prevention and early treatment. In: Helmchen H, Sartorius N (eds) Ethics in psychiatry—European contributions. Springer Science + Business Media B.V, Heidelberg, pp 235–262CrossRef

38.

Klosterkötter J, Schultze-Lutter F, Bechdolf A, Ruhrmann S (2011) Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiatry 10:165–174PubMedPubMedCentral

39.

Klosterkötter J, Schultze-Lutter F, Ruhrmann S (2008) Kraepelin and psychotic prodromal conditions. Eur Arch Psychiatry Clin Neurosci 258:74–84PubMedCrossRef

40.

Köhn D, Pukrop R, Niedersteberg A et al (2004) pathways to care: help-seeking behavior in first-episode psychosis. Fortschr Neurol Psychiatry 72:635–642CrossRef

41.

Koutsouleris N, Riecher-Rössler A, Meisenzahl EM et al (2014) Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers. Schizophr Bull. doi:10.1093/schbul/sbu078

42.

Lee TY, Shin YS, Shin NY et al (2014) Neurocognitive function as a possible marker for remission from clinical high risk for psychosis. Schizophr Res 153:48–53PubMedCrossRef

43.

Lip GY, Edwards SJ (2006) Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 118:321–333PubMedCrossRef

44.

Marshall M, Lockwood A (2004) Early intervention for psychosis. Cochrane Database Syst Rev 4:CD004718

45.

McGlashan T, Walsh B, Woods SW (2010) The psychosis-risk syndrome. Handbook for diagnosis and follow-up. Oxford University Press, New York

46.

McGlashan TH, Zipursky RB, Perkins D et al (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163:790–799PubMedCrossRef

47.

McGorry PD, Nelson B, Phillips LJ et al (2013) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. Journal clin psychiatry 74:349–356CrossRef

48.

McGorry PD, Yung AR, Phillips LJ (2003) The “close-in” or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull 29:771–790PubMedCrossRef

49.

McGorry PD, Yung AR, Phillips LJ et al (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59:921–928PubMedCrossRef

50.

Michel C, Ruhrmann S, Schimmelmann BG, Klosterkötter J, Schultze-Lutter F (2014) A stratified model for psychosis prediction in clinical practice. Schizophr Bull. doi:10.1016/j.schres.2014.01.025 PubMed

51.

Michel C, Schimmelmann BG, Kupferschmid S, Siegwart M, Schultze-Lutter F (2014) Reliability of telephone assessments of at-risk criteria of psychosis: a comparison to face-to-face interviews. Schizophr Res 153:251–253PubMedCrossRef

52.

Miklowitz DJ, O’Brien MP, Schlosser DA et al (2014) Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry 53:848–858PubMedCrossRef

53.

Morrison AP, French P, Stewart SL et al (2012) Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 344:e2233CrossRefPubMedCentral

54.

Morrison AP, French P, Walford L et al (2004) Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 185:291–297PubMedCrossRef

55.

Mössner R, Schuhmacher A, Wagner M et al (2010) Daoa/g72 predicts the progression of prodromal syndromes to first episode psychosis. Eur Arch Psychiatry Clin Neurosci 260:209–215PubMedCrossRefPubMedCentral

56.

Mrazek PJ, Haggerty HJ (1994) Reducing risks for mental disorders: frontiers for preventive research. Academy Press, Washington

57.

Nelson B, Yuen HP, Wood SJ et al (2013) Long-term follow-up of a group at ultra high risk (“prodromal”) for psychosis: the pace 400 study. JAMA Psychiatry 70:793–802PubMedCrossRef

58.

Nieman DH, Ruhrmann S, Dragt S et al (2013) Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables. Schizophr Bull. doi:10.1093/schbul/sbt145 PubMed

59.

Nieman DH, Velthorst E, Becker HE et al (2013) The strauss and carpenter prognostic scale in subjects clinically at high risk of psychosis. Acta Psychiatr Scand 127:53–61PubMedCrossRef

60.

Nuechterlein KH, Dawson ME, Gitlin M et al (1992) Developmental processes in schizophrenic disorders: longitudinal studies of vulnerability and stress. Schizophr Bull 18:387–425PubMedCrossRef

61.

Olvet DM, Carrion RE, Auther AM, Cornblatt BA (2013) Self-awareness of functional impairment in individuals at clinical high-risk for psychosis. Early Interv Psychiatry. doi:10.1111/eip.12086 PubMed

62.

Perez VB, Woods SW, Roach BJ et al (2014) Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. Biol Psychiatr 75:459–469CrossRef

63.

Perkins DO, Jeffries CD, Addington J et al (2014) Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the napls project. Schizophr Bull. doi:10.1093/schbul/sbu099

64.

Piskulic D, Addington J, Cadenhead KS et al (2012) Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res 196:220–224PubMedCrossRefPubMedCentral

65.

Preti A, Cella M (2010) Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res 123:30–36PubMedCrossRef

66.

Pukrop R, Ruhrmann S (2012) Neurocognitive indicators of high-risk states for psychosis. In: Borgwardt S, McGuire P, Fusar Poli P (eds) Vulnerability to psychosis: from neuroscience to psychopathology. Psychology Press, Hove, pp 73–94

67.

Riecher-Rössler A, Aston J, Ventura J et al (2008) the basel screening instrument for psychosis (BSIP): development, structure, reliability and validity. Fortschr Neurol Psychiatr 76:207–216PubMedCrossRef

68.

Riecher-Rössler A, Pflueger MO, Aston J et al (2009) Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. Biol Psychiatry 66:1023–1030PubMedCrossRef

69.

Rössler W, Salize HJ, van Os J, Riecher-Rössler A (2005) Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 15:399–409PubMedCrossRef

70.

Ruhrmann S, Klosterkötter J, Bodatsch M et al (2012) Pharmacological prevention and treatment in clinical at-risk states for psychosis. Curr Pharm Des 18:550–557PubMedCrossRef

71.

Ruhrmann S, Klosterkötter J, Bodatsch M et al (2012) Chances and risks of predicting psychosis. Eur Arch Psychiatry Clin Neurosci 262(Suppl 2):S85–S90PubMedCrossRef

72.

Ruhrmann S, Schultze-Lutter F, Klosterkötter J (2003) Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 36(Suppl 3):S162–S167PubMed

73.

Ruhrmann S, Schultze-Lutter F, Klosterkötter J (2010) Probably at-risk, but certainly ill—advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res 120:23–37PubMedCrossRef

74.

Ruhrmann S, Schultze-Lutter F, Klosterkötter J (2010) Sub-threshold states of psychosis—a challenge to diagnosis and treatment. Clin Neuropsychiatry 7:72–87

75.

Ruhrmann S, Schultze-Lutter F, Salokangas RK et al (2010) Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 67:241–251PubMedCrossRef

76.

Salokangas RK, Heinimaa M, From T et al (2014) Short-term functional outcome and premorbid adjustment in clinical high-risk patients. Results of the epos project. Eur Psychiatry 29:371–380PubMedCrossRef

77.

Salokangas RK, Nieman DH, Heinimaa M et al (2013) Psychosocial outcome in patients at clinical high risk of psychosis: a prospective follow-up. Soc Psychiatry Psychiatr Epidemiol 48:303–311PubMedCrossRef

78.

Salokangas RKR, Ruhrmann S, von Reventlow HG et al (2012) Axis i diagnoses and transition to psychosis in clinical high-risk patients epos project: prospective follow-up of 245 clinical high-risk outpatients in four countries. Schizophr Res 138:192–197PubMedCrossRef

79.

Schaffner N, Schimmelmann BG, Niedersteberg A, Schultze-Lutter F (2012) pathways-to-care for first-episode psychotic patients–an overview of international studies. Fortschr Neurol Psychiatr 80:72–78PubMedCrossRef

80.

Schimmelmann BG, Walger P, Schultze-Lutter F (2013) The significance of at-risk symptoms for psychosis in children and adolescents. Can J psychiatry Revue canadienne de psychiatrie 58:32–40

81.

Schmidt SJ, Grunert VM, Schimmelmann BG, Schultze-Lutter F, Michel C (2014) Differences in coping, self-efficacy, and external control beliefs between patients at-risk for psychosis and patients with first-episode psychosis. Psychiatry Res 219:95–102PubMedCrossRef

82.

Schmidt SJ, Schultze-Lutter F, Schimmelmann BG et al (2015) EPA guidance on the early intervention in clinical high-risk states of psychoses. European Psychiatry (in press)

83.

Schultze-Lutter F (2009) Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull 35:5–8PubMedCrossRefPubMedCentral

84.

Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J (2007) Schizophrenia proneness instrument - adult version (spi-a). Giovanni Fioriti, Rome

85.

Schultze-Lutter F, Klosterkötter J, Picker H, Steinmeyer E, Ruhrmann S (2007) Predicting first-episode psychosis by basic symptom criteria. Clin Neuropsychiatry 4:11–22

86.

Schultze-Lutter F, Klosterkötter J, Ruhrmann S (2014) Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms. Schizophr Res 154:100–106PubMedCrossRef

87.

Schultze-Lutter F, Michel C, Schmidt SJ et al (2015) EPA guidance on the early detection of clinical high risk states of psychoses. European Psychiatry (in press)

88.

Schultze-Lutter F, Ruhrmann S, Berning J, Maier W, Klosterkötter J (2010) Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull 36:182–191PubMedCrossRefPubMedCentral

89.

Schultze-Lutter F, Schimmelmann BG, Ruhrmann S, Michel C (2013) ‘A rose is a rose is a rose’, but at-risk criteria differ. Psychopathology 46:75–87PubMedCrossRef

90.

Smieskova R, Fusar-Poli P, Allen P et al (2010) Neuroimaging predictors of transition to psychosis-a systematic review and meta-analysis. Neurosci Biobehav Rev 34:1207–1222PubMedCrossRef

91.

Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T (2013) Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 346:f185PubMedCrossRefPubMedCentral

92.

Tarbox SI, Addington J, Cadenhead KS et al (2013) Premorbid functional development and conversion to psychosis in clinical high-risk youths. Dev Psychopathol 25:1171–1186PubMedCrossRef

93.

Valmaggia LR, Stahl D, Yung AR et al (2013) Negative psychotic symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: a latent class cluster analysis study. Psychol Med 43:2311–2325PubMedCrossRef

94.

van der Gaag M, Nieman DH, Rietdijk J et al (2012) Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull 38:1180–1188PubMedCrossRefPubMedCentral

95.

van der Gaag M, Smit F, Bechdolf A et al (2013) Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res 149:56–62PubMedCrossRef

96.

van Tricht MJ, Ruhrmann S, Arns M et al (2014) Can quantitative EEG measures predict clinical outcome in subjects at clinical high risk for psychosis? A prospective multicenter study. Schizophr Res 153:42–47PubMedCrossRef

97.

Velthorst E, Nieman DH, Linszen D et al (2010) Disability in people clinically at high risk of psychosis. Br J Psychiatry 197:278–284PubMedCrossRef

98.

von Reventlow HG, Kruger-Ozgurdal S, Ruhrmann S et al (2014) Pathways to care in subjects at high risk for psychotic disorders: a European perspective. Schizophr Res 152:400–407CrossRef

99.

WHO (2004) Prevention of mental disorders: Effective interventions and policy options. World Health Organization, Geneva

100.

Wu EQ, Birnbaum HG, Shi L et al (2005) The economic burden of schizophrenia in the united states in 2002. Journal Clin Psychiatry 66:1122–1129CrossRef

101.

Yung A, Phillips L, Simmons MB et al (2006) CAARMS—comprehensive assessment of at risk mental states. The PACE Clinic. University of Melbourne, Melbourne

102.

Yung AR, Nelson B, Thompson A, Wood SJ (2010) The psychosis threshold in ultra high risk (prodromal) research: is it valid? Schizophr Res 120:1–6PubMedCrossRef

103.

Zimmermann R, Gschwandtner U, Wilhelm FH et al (2010) EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis. Schizophr Res 123:208–216PubMedCrossRef

Titel: Prediction and prevention of psychosis: current progress and future tasks
verfasst von: Stephan Ruhrmann
Frauke Schultze-Lutter
Stefanie J. Schmidt
Nathalie Kaiser
Joachim Klosterkötter
Publikationsdatum: 01.11.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe Sonderheft 1/2014
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-014-0541-5

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2014

Multistage drug effects of ketamine in the treatment of major depression

Selected issues of the DGPPN Congress in 2013

Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer’s disease

Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis